Subscribe
Subscribe
MY AMERICAN SCIENTIST
LOG IN! REGISTER!
SEARCH
 
Logo IMG
HOME > MULTIMEDIA > Multimedia Detail

SCIENCE IN THE NEWS DAILY

Promising Alzheimer's Drug Approved for Late-Stage Trials

from USA Today

An experimental drug for Alzheimer's disease patients showed promise in Phase II clinical trials and is moving into final-stage trials, Wyeth and Elan, the makers of bapineuzumab, announced Tuesday.

Bapineuzumab is designed to fight beta amyloid, a toxic protein that clumps together in the brains of Alzheimer's patients.

In the early studies, conducted around the USA, 240 people with early- to moderate-stage Alzheimer's disease were either assigned bapineuzumab or a placebo. Researchers reported that non-carriers of a gene considered to be a risk factor for Alzheimer's disease, called ApoE4, showed "clinically meaningful benefits" in a battery of tests used to track the progression of Alzheimer's disease.

Read more ...


comments powered by Disqus
 

EMAIL TO A FRIEND :

Of Possible Interest

Science In The News Daily: Three Doctors Charged in Armstrong Doping Case

Science In The News Daily: Fish Oil Fail: Omega-3s May Not Protect Brain Health After All

Science In The News Daily: Antibody Cocktail Cures Monkeys of Ebola

Subscribe to American Scientist